MYGN · Myriad Genetics, Inc. · Stock research

Current Thesis

Myriad is a legacy hereditary-cancer testing house (BRACAnalysis, GeneSight, Prolaris) trying to buy its way back into a growth narrative through ctDNA/minimal-residual-disease (MRD) testing. The narrative leg on offer: the June 23, 2026 expansion of Precise MRD into breast, colorectal and renal cancers, backed by the MONITOR-Breast publication (93% baseline ctDNA detection, 100% specificity for predicting pathological complete response). That print sparked a +9.2% session on June 24 off a base near 52-week lows. The problem is that one press release is not narrative velocity: core revenue grew just 2% YoY in Q1 (reported May 5), adjusted EBITDA was negative ($-4.5M), and the stock sits around $4.50 versus an $8.59 high a year ago. This is the cheap-multiple, rolled-over-structure profile the playbook treats as a value trap until price proves otherwise a watch, not a fresh entry.

Bullish and bearish views on Myriad Genetics, Inc.

The model's bull view on Myriad Genetics, Inc. (MYGN), in brief: MRD is the only growth vector that re-rates this name. The bear view: Decelerating core, negative EBITDA. Q1 (May 5): revenue $200.4M, up only 2% YoY and a hair light of the ~$202.4M consensus; adjusted EPS -$0.09 missed the -$0.07 estimate; the stock fell ~14% on the print. Prenatal is bleeding. Prenatal Health revenue -15% YoY to $41.9M in Q1… Both cases follow in full.

Bull Case

• MRD is the only growth vector that re-rates this name. June 23, 2026: Precise MRD expanded to breast/colorectal/renal a whole-genome-sequencing assay tracking up to 1,000 variants, pitched as higher-sensitivity than tumor-informed competitors. Addressable pool cited at 6M+ U.S. patients.
• MONITOR-Breast data is clinically real. Published in Future Oncology (June 23, 2026): 100% specificity for pCR prediction and 44% more at-risk patients caught with longitudinal vs single-timepoint testing the kind of evidence reimbursement decisions hinge on.
• Mental Health is quietly compounding. GeneSight revenue +24% YoY to $38.3M in Q1 (May 5), the fastest-growing segment.
• Second product catalyst loaded. Prolaris AI (prostate) launch guided for Q2 2026; management framed MRD + Prolaris AI as "important drivers of growth in 2027 and beyond."
• Guidance reaffirmed. FY2026 revenue held at $860–880M with 2H expected above 1H (May 5), and net cash is roughly neutral ($124.4M cash vs $120.3M long-term debt at March 31).
• Sell-side leaves upside if the pivot works. Goldman maintains Buy with a $14 target (cut from $18); consensus targets span $4–$18 against a ~$4.50 tape.

Bear Case

• Decelerating core, negative EBITDA. Q1 (May 5): revenue $200.4M, up only 2% YoY and a hair light of the ~$202.4M consensus; adjusted EPS -$0.09 missed the -$0.07 estimate; the stock fell ~14% on the print.
• Prenatal is bleeding. Prenatal Health revenue -15% YoY to $41.9M in Q1, offsetting cancer growth.
• Late entrant into a brutal, reimbursement-gated market. Precise MRD competes against Natera's Signatera (Medicare-covered, scaled), Guardant Reveal, and Exact Sciences Oncodetect/Cancerguard. Coverage and volume not a single publication decide MRD winners, and Myriad is behind.
• Structure is broken, not basing. Sub-$5 print, near the $3.53 52-week low, down from $8.59; the June 24 pop is a news bounce inside a downtrend.
• Targets are drifting the wrong way. TD Cowen cut to $6 (from $7) and Goldman to $14 (from $18) Hold consensus, falling estimates.
• Sub-$5 / ~$428M-cap liquidity risk amplifies volatility and makes the name a poor momentum vehicle.

Setup & Price Structure

Price sits ~$4.50 (June 22–24 range $4.43–$4.79), bouncing off a June low of $3.99 and a 52-week low of $3.53; the 52-week high is $8.59. The June 24 +9.2% session put in a higher low against the June floor, the first constructive tell in months, but the name remains below any reclaimable longer-term moving average and the move came on a single catalyst rather than cluster confirmation across the MRD complex. RSI in the mid-60s reflects the pop, not an established uptrend. Social/retail interest is dead, so there is no squeeze fuel and no saturation signal either way. The honest read: this is a beaten-down turnaround testing whether one piece of clinical evidence can mark a bottom strength would need to hold above the $3.99 base and reclaim prior shelves before any of it is tradable.

Catalyst Calendar (next 30 days)

• Ongoing: Precise MRD reimbursement/coverage decisions and any follow-on data the variable that actually moves the MRD thesis; unscheduled.
• ~2026-08-05 (est., outside 30d): Q2 2026 earnings, based on the company's historical early-August cadence; Street modeling ~$218.9M revenue. Binary for the 2H>1H guidance claim treat as a blackout for any fresh exposure as it approaches.

Elapsed catalysts

• ~End of Q2 2026 (by ~2026-06-30): Prolaris AI (prostate) commercial launch guided "Q2 2026" on the May 5 call, no firm date; a launch announcement is the most likely near-term news item. _(passed 15d ago)_

What Would Change Our Mind

The read flips constructive if Precise MRD secures a concrete coverage/reimbursement win or volume disclosure, the Prolaris AI launch lands on schedule, and price builds a higher-low structure that reclaims prior shelves on rising volume with the broader MRD/liquid-biopsy group participating that converts a single-news bounce into an accelerating pivot worth sizing. It stays a pass if Precise MRD remains an evidence story with no reimbursement traction, Prolaris AI slips, and the tape fails to hold its June base. The most useful disconfirming signal: a Q2 print in early August that does not show the promised 2H acceleration.

Correlation Notes

MYGN trades with the ctDNA/liquid-biopsy and MRD complex Natera (NTRA), Guardant Health (GH), Exact Sciences (EXAS), Tempus (TEM), Veracyte (VCYT) and with small-cap diagnostics/biotech beta (XBI) and risk appetite generally. It is acutely sensitive to Medicare/CMS reimbursement policy, the structural lever for every MRD name. As a sub-$5, ~$428M-cap stock, single-name news (a coverage decision, a data readout, a guidance change) dominates its moves more than sector beta, and thin liquidity makes both legs sharper. A genuine MRD theme acceleration would show up first in the larger, more liquid peers (NTRA, GH) before reaching this name.

Notes

This is a value/turnaround profile, not the accelerating-narrative setup the playbook hunts keep it on watch until structure and reimbursement traction confirm the pivot.